Dysregulation of hypothalamic modulation in olanzapine treated male rats


Sezlev-Bilecen D., AK M., YANIK T.

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, cilt.71, ss.103-107, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 71
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.pnpbp.2016.06.012
  • Dergi Adı: PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.103-107
  • Anahtar Kelimeler: Atypical antipsychotics, Olanzapine, Hypothalamic neuropeptides, Weight gain, Serotonin, Arcuate nucleus, WEIGHT-GAIN, NEUROPEPTIDE-Y, ASSOCIATION, LEPTIN, ANTIPSYCHOTICS, SCHIZOPHRENIA, POLYMORPHISM, ZIPRASIDONE, EXPRESSION, MECHANISM
  • Orta Doğu Teknik Üniversitesi Adresli: Evet

Özet

The mechanism of weight gain through application of olanzapine, a serotonin and dopamine receptor antagonist has not been fully understood. Weight gain and food intake are under the control of various neurohormones; POMC (proopiomelanocortin), CART (cocaine and amphetamine regulated transcript), AgRP (Agouti-related peptide) and NPY (neuropeptide Y) that are majorly synthesized and secreted from the arcuate nucleus (ARC) of hypothalamus. In this study, the alteration of the ARC neurohormone levels in rats were determined as one of the weight gain mechanisms. To understand the underlying mechanism of olanzapine-induced weight gain, the drug was orally administrated to healthy male Wistar rats for analysis of both the hypothalamic gene expression and peripheral levels of those candidate neuropeptides. In rats hypothalamic mRNA levels of NPY, AgRP and POMC decreased while CART levels did not show any alteration. Consistently, circulating levels of NPY, AgRP and alpha-MSH decreased significantly yet CART levels were also reduced. In conclusion, it may be presumed that the antagonistic effect of olanzapine on the ARC neurons might be the onset for a dysregulation of the neurohormones secretion which may cause weight gain during treatment. (C) 2016 Elsevier Inc. All rights reserved.